• Home
  • News
  • SkinBioTherapeutics CEO, Cath O’Neill named as one of 50 Movers and Shakers in BioBusiness 2017 report

SkinBioTherapeutics CEO, Cath O’Neill named as one of 50 Movers and Shakers in BioBusiness 2017 report

Manchester, UK – 2 November 2017 – SkinBioTherapeutics plc (AIM: SBTX, the “Company”), CEO Dr Cath O’Neill has been recognised as one of the top 50 female leaders in healthcare business in the UK as part of BioBusiness’ 2017 50 Movers and Shakers report.

The annual report published by BioBeat aims to celebrate exceptional female leaders and bioentrepreneurs who are driving innovative thinking within the UK healthcare industry making significant contributions to the success of the sector.

Dr O’Neill has been recognised for her research within the skin microbiome sector, work which resulted in her co-founding SkinBioTherapeutics, a life sciences company focusing on skin health.

SkinBioTherapeutics’ SkinBiotix® platform is based on lysate derived from probiotic bacteria and this technology is being applied to skin health. The Company has three programmes in development – in cosmetic skin care, anti-infection and skin repair – all multi-billion dollar markets.

In 2017, the Company has seen both financial and scientific success, having originally spun-out from The University of Manchester. In April 2017, it completed an IPO and was admitted to AIM raising £4.5m, and recently, its technology passed third party validated, cell toxicity tests. The Company is on track for its first programme to enter human trials in 2018.

Dr. Cath O’Neill, CEO of SkinBioTherapeutics, commented:

“I am honoured to be named as one of the UK’s leading women in the healthcare industry as part of the BioBeat 2017 report. The public recognition of women within the healthcare arena is important to encourage the next generation coming through.

“Developing a range of viable skin health products based on the SkinBiotix® technology is at the core of our business and I am proud of the results we have achieved so far. In the new arena of skin microbiome, our work is already attracting notice from the skin care industry. By driving forward our programmes, the result could be a range of products that could make a significant difference – not only to people with sensitive skin but also to healthcare professionals.”

The 2017 report has been released ahead of BioBeat’s event held at the Francis Crick Institute on Thursday 16 November 2017. This year’s event focuses on re-shaping biotech partnering to make a greater impact on health and wealth.

CONTACT US
  • Home
  • News
  • SkinBioTherapeutics CEO, Cath O’Neill named as one of 50 Movers and Shakers in BioBusiness 2017 report